Immunocore Holdings plc

NasdaqGS:IMCR 주식 보고서

시가총액: US$1.7b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Immunocore Holdings 미래 성장

Future 기준 확인 1/6

Immunocore Holdings (는) 각각 연간 22.7% 및 17.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 21.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -87.6% 로 예상됩니다.

주요 정보

22.7%

수익 성장률

21.1%

EPS 성장률

Biotechs 수익 성장24.2%
매출 성장률17.6%
향후 자기자본 수익률-87.6%
애널리스트 커버리지

Good

마지막 업데이트06 Jun 2024

최근 미래 성장 업데이트

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Jun 16
Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

May 11
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Apr 05
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Jan 22
Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Jan 21

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Dec 18
Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

May 08
Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16
Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Immunocore: Attractive Commercial-Stage Biopharma

Oct 05

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Aug 12
Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Aug 10

Immunocore to raise $140M in private placement financing

Jul 18

Analysts Are Updating Their Immunocore Holdings plc (NASDAQ:IMCR) Estimates After Its Second-Quarter Results

Aug 15
Analysts Are Updating Their Immunocore Holdings plc (NASDAQ:IMCR) Estimates After Its Second-Quarter Results

수익 및 매출 성장 예측

NasdaqGS:IMCR - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026356-136-85-1312
12/31/2025332-122-83-7516
12/31/2024304-103-38-2916
3/31/2024265-60-15-12N/A
12/31/2023249-55-23N/A
9/30/2023234-661421N/A
6/30/2023231-632026N/A
3/31/2023201-52-6-1N/A
12/31/2022174-53-51-49N/A
9/30/2022114-62-55-54N/A
6/30/202282-112-96-94N/A
3/31/202253-156-134-133N/A
12/31/202136-180-144-143N/A
9/30/202137-150-137-135N/A
6/30/202139-139-111-110N/A
3/31/202142-116-83-78N/A
12/31/202041-101-88-84N/A
9/30/202037-105-91-86N/A
6/30/202034-109-137-131N/A
3/31/202033-120-146-141N/A
12/31/201934-138-142-136N/A
12/31/201830-91-26-21N/A
12/31/201719-66N/A-82N/A
12/31/201620-29N/A-45N/A
12/31/20151720N/A-26N/A
9/30/201410-9N/A65N/A
9/30/20133-6N/A18N/A

애널리스트 미래 성장 예측

수입 대 저축률: IMCR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: IMCR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: IMCR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: IMCR 의 수익(연간 17.6% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: IMCR 의 수익(연간 17.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: IMCR (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견